Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.5.1.1 (asparaginase)
 2,695 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Factor VIII/von Willebrand factor (VIII/vWf) related properties were studied in 10 patients affected by acute lymphoblastic leukemia during L-asparaginase-vincristine-prednisone treatment. These properties remained within the normal range during the period of observation without any difference from the basal values. On the contrary, VIII:C activity was already increased before medication and showed gradual additional elevation during the observation period, reaching a peak 1 week after discontinuation of L-asparaginase administration. Crossed immunoelectrophoresis of vWf, performed weekly in 2 patients during the period of medication, demonstrated a normal pattern before the beginning of treatment, but an apparently faster migrating peak during L-asparaginase therapy, suggesting a qualitative abnormality of vWf. No abnormal bleeding tendency was found in any of the patients.
 ...
PMID:Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia. 250 99

The glycoprotein fibronectin is, as well as by various other cells, also produced in leucocytes and is said to play an important role in malignant transformation of cells. Therefore, the behaviour of plasma fibronectin and of factor VIII R:AG was investigated in acute leukaemia in order to prove their significance as prognostic and therapeutic markers (method: electroimmunoassay). In patients with acute myeloid leukaemia (n = 29) and acute lymphoblastic leukaemia (n = 11) no significant changes in fibronectin concentration could be evaluated. Fibronectin levels declined significantly only during therapy with asparaginase in patients with acute lymphoblastic leukaemia, probably as a result of disturbed synthesis in the liver. Using crossed immunoelectrophoresis against fibronectin antiserum, one normal and one slower migrating antigen (FN:C) could be observed in nearly all plasma samples in patients with acute leukaemia. By means of in vitro tests with highly purified substances and intermediate gel electrophoresis it could be shown that FN:C represents fibronectin which has bound fibrinogen, probably crosslinked by activated factor XIII. Factor VIII R:AG was found to be greatly raised in patients with acute leukaemia--up to 1400% of the normal level. Increased levels correlated well with a worsening of the disease. The protein seems to be suitable for estimating the activity and prognosis of acute leukaemia.
 ...
PMID:Fibronectin and factor VIII-related antigen in acute leukaemia. 640 58

An extra-corporeal chamber has been constructed and used for diagnosis, enzyme therapy and immuno-adsorption. The chamber is made from polymethyl-acrylate and the dimensions of the chamber are 10 x 18 x 7 cm. It contains 23 plates with a total area of 0.5 m2. In most cases no pump is used. The active substance is bound covalently to the plate surfaces. The time for each hemoperfusion has been 3-6 hr. No infections, decrease of thrombocytes or other side effects have been observed. By immobilized homologous antisera (F (ab')2), three putative tumour-associated antigens were isolated from cases of hypernephroma. Two children and one adult patient with malignant lymphoma were treated with extra-corporeal L-asparaginase, the latter with repeated remissions of metastases. The level of antibodies against Factor VIII was significantly decreased by chamber immunoadsorption in two cases of hemophilia. A number of kidney transplantation cases received extra-corporeal L-asparaginase pre- and post-operatively to counteract rejection. In all around 50 patients have received extra-corporeal treatment without any adverse effects. The use of the extra-corporeal chamber in other diseases is discussed.
 ...
PMID:Enzyme therapy and immuno-adsorption by an extra-corporeal device. 698 19